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Objectives. Since subjects may have been diagnosed before cohort entry, analysis of late HIV diagnosis (LD) is usually restricted to
the newly diagnosed. We estimate the magnitude and risk factors of LD in a cohort of seroprevalent individuals by imputing ser-
oconversion dates. Methods. Multicenter cohort of HIV-positive subjects who were treatment naive at entry, in Spain, 2004–2008.
Multiple-imputation techniques were used. Subjects with times to HIV diagnosis longer than 4.19 years were considered LD.
Results. Median time to HIV diagnosis was 2.8 years in the whole cohort of 3,667 subjects. Factors signiﬁcantly associated with LD
were: male sex; Sub-Saharan African, Latin-American origin compared to Spaniards; and older age. In 2,928 newly diagnosed sub-
jects,mediantimetodiagnosiswas3.3years,andLDwasmorecommonininjectingdrugusers.Conclusions.Estimatesofthemag-
nitude and risk factors of LD for the whole cohort diﬀer from those obtained for new HIV diagnoses.
1.Introduction
The majority of clinical cohorts of HIV-infected people are
made up of seroprevalent subjects whose dates of serocon-
versionareunknown[1–3].Ser oprevalentsubjectsha v ebeen
used to quantify the magnitude and risk factors of late diag-
nosis of HIV infection, an important public health problem
which, by deﬁnition, cannot be studied in seroconverter
cohorts [4, 5]. Although there are multiple deﬁnitions of late
diagnosis based on diﬀerent biological markers [4, 6–8],
most of them are based on the patient’s CD4 lymphocyte
count close to the date of HIV diagnosis. For some persons,
HIV may have been diagnosed before their inclusion in
a clinical cohort; therefore, no CD4 counts close to HIV
diagnosis are usually available. Consequently, these people
are ignored, and estimates are obtained only from those with
available CD4 counts—largely the new HIV diagnoses—
rather than from the whole cohort. Most clinical cohorts
include newly diagnosed people as well as people who have
been diagnosed in the past, but the latter group is rendered2 AIDS Research and Treatment
invisible. The use of multiple imputation techniques to
estimate the time between HIV seroconversion and HIV di-
agnosis could overcome the aforementioned problem. These
techniques, which so far have not been applied to study late
HIV diagnosis, are based on the correlation between certain
biologicalmarkerslikeCD4lymphocytesandthedurationof
infection [9–11].
The magnitude of late HIV diagnoses in the subgroup of
new HIV diagnoses in cohorts from industrialized countries
ranges from 18% to 39% [4, 5, 12–14]. For these cohorts,
the proportion of subjects who are new HIV diagnoses—and
thereforecanbeanalyzed—rangesfrom4%to73%[4,5,12–
15]. In Spain, considering late diagnosis as subjects with
a CD4 lymphocyte count of <200cells/mm3 or an AIDS-
deﬁning disease in the ﬁrst year after HIV diagnosis, we
reported 37% of late diagnosis in 2004–06 in the 68% of
subjects who could be evaluated because they were newly
diagnosed at inclusion in the cohort [16]. Risk of late di-
agnosis increased with age, was higher in men than in
women, and, contrary to previous publications [12, 17, 18],
was higher in heterosexuals and injection drug users (IDUs)
compared to men who have sex with men (MSM). We
hypothesized that this unexpected ﬁnding may reﬂect that
the new diagnoses represent a diﬀerent population than the
old ones, which could not be evaluated for late diagnosis
analyses [16]. To test this hypothesis, we estimated the mag-
nitude and risk factors of late HIV diagnosis, in all cohort
members and separately in those newly diagnosed, in a mul-
ticenter cohort of seroprevalent subjects in Spain for whom
we have imputed their HIV seroconversion dates.
2. Methods
CoRIS is an open, multicenter, and prospective cohort of
adultpatientswithconﬁrmedHIVinfectionwhoarenaiveto
antiretroviral treatment (ART) at the ﬁrst visit to any of the
CoRIS centers and who agree to participate in the study by
signing an informed consent form. A complete description
has been published elsewhere [19]. Brieﬂy, CoRIS collects a
minimum dataset which is subject to internal and external
quality controls. Between January 2004 and October 2008,
4,057 subjects were recruited from 27 participating centers
where the percentage of CD4 lymphocytes (hereinafter re-
ferred to as “CD4%”) was measured. A total of 231 subjects
were excluded because they had recently been recruited, and
no CD4% results were available, and 159 were excluded be-
cause their ﬁrst CD4% values were recorded after ART initi-
ation. Accordingly, 3,667 patients were available for analysis.
Subjects were classiﬁed as late diagnosis (LD) when the
diagnosis of HIV infection was made more than 4.19 years
after seroconversion. This cut-oﬀ point was chosen because,
in a previous publication [20], it was estimated that this
was the time elapsed from seroconversion to reaching a CD4
threshold of <350. In turn, this CD4 lymphocyte threshold is
used in the new deﬁnition of late presentation recommended
by the European Late Presenter Consensus Working Group
[6].
A multiple imputation technique was used to estimate
the date of seroconversion of all CoRIS subjects, based on
the model for progression of infection described by Mu˜ noz
et al. [10], which has been used in Spain [11]. These au-
thors use parametric survival models based on the Weibull
distribution to estimate the time elapsed between the date
of HIV seroconversion and the date of ﬁrst CD4% in the
absence of ART, on the basis of that ﬁrst CD4%. Their
paper describes the model’s parameter for each of the ﬁve
thresholds in which CD4% is categorized.
This model and its coeﬃcients allow us to know the
probabilitythatthedateofseroconversionfallsbeforeagiven
date, conditioned by the fact that it must be between the
date when the subject started being at risk for HIV infection
and the date of HIV diagnosis. From this model equation,
we can estimate (impute) the timespan between the date
of seroconversion and the date of HIV diagnosis when the
following information is made available for each subject: (a)
date when the subject started being at risk for HIV infection,
(b) date of HIV diagnosis, and (c) the value of CD4% and
the date it was measured.
We used the following imputation process: (1) for each
individual, a random number was drawn from a Weibull
distribution with the parameters corresponding to his/her
CD4% threshold, which was considered a random estimate
of the timespan between the date of seroconversion and the
date of ﬁrst CD4% (t). This made it possible to calculate the
timespan between the date of seroconversion and the date
of HIV diagnosis (“time to HIV diagnosis”, t1), and the date
of seroconversion as the diﬀerence between the date of ﬁrst
CD4% minus time t. Subjects whose time t1 was longer than
4.19 years were considered late diagnoses. (2) The preceding
process was replicated 20 times. Twenty diﬀerent databases
were generated with the information obtained in each rep-
lication. (3) The subsequent analyses were made by combin-
ing the results obtained when analyzing these 20 databases
separately.
We also present the results obtained using the deﬁnition
that classiﬁed subjects as delayed diagnosis (DD) when they
had a CD4 lymphocyte count of <350cells/mm3 in the ﬁrst
year after HIV diagnosis or an AIDS-deﬁning disease in the
ﬁrst three months after HIV diagnosis. Thus, this deﬁnition
only permitted the evaluation of subjects for whom that
information was available, that is, the new HIV diagnoses.
We assumed that the date when a subject started being
at risk for HIV infection was the beginning of the epidemic
in Spain, 1 January 1980, except in (a) patients infected by
the sexual route or by injecting drug use who were born after
1 January 1965; for these subjects, we used the date of their
15thbirthday,and(b)patientsintheremainingtransmission
categories who were born after 1 January 1980, for whom we
used their date of birth.
We present a descriptive analysis of the characteristics of
subjects included in the analysis, as well as their time to HIV
diagnosis.Weusedananalysisofvarianceforthecomparison
of means, to compare the time to HIV diagnosis according to
patient characteristics.
To evaluatethe factorsindependently associated withlate
diagnosis, we used a multivariate logistic regression model.
In this model, robust methods were used to estimate the
conﬁdence intervals, assuming correlation among subjectsAIDS Research and Treatment 3
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Figure 1: Distribution of date of seroconversion and date of HIV
diagnosis.
recruited in each center and independence between subjects
in diﬀerent centers [21].
The analyses were performed using R version 2.13 [22]
and Stata 11.
3. Results
Of the 3,667 patients included in this analysis, most were
men (77.8%), were infected by sexual transmission (43.1%
MSM and 37.5% heterosexual), and were Spanish nationals
(68.5%); 15.8% had been infected through injecting drug
use. The mean age at HIV diagnosis was 34.8 years (SD =
10.2) and the median follow-up time was 1.38 years. At
cohort entry, 442 patients (12%) had been diagnosed with
AIDS, another 191 (5.2%) developed AIDS, and 86 persons
(2.3%) died during followup.
3.1. Description of Time from Imputed Seroconversion to
HIV Diagnosis
3.1.1. Results for All Subjects Included in the Cohort (n =
3667). The distribution of the dates of HIV diagnosis and
the mean imputed seroconversion date per individual can be
seen in Figure 1. The shape of the ﬁgure is similar in both
cases, but with a shift over time. The median date of HIV
diagnosiswasOctober2005(IQR:June2004–February2007)
while the median date of seroconversion was February 2002
(IQR: May 1999–May 2004).
Table 1 shows the distribution of years elapsed between
the mean imputed date of seroconversion and the date of
HIV diagnosis. Overall, the median time to HIV diagnosis
was 2.8 years (IQR: 1.2–5.2).
Time to HIV diagnosis was longer in men, in persons
with heterosexual or “other” routes of transmission (vertical,
transfusions, tattoos, ...), and, in those from countries other
than Spain, it also increased with age at HIV diagnosis and
waslongerinpatientswhodevelopedAIDSandinthosewho
died.
Table 2 shows the distribution of late diagnosis according
to the sociodemographic characteristics of the subjects and
the odds ratio based on the multivariate analysis. Factors
independently associated with late diagnosis in the multi-
variate analysis were male gender, place of origin Sub-Sa-
haran Africa or Latin America, and older age at HIV diag-
nosis. Subjects with heterosexual transmission had a higher
frequency of late diagnoses than MSM although that higher
frequency did not attain statistical signiﬁcance.
3.1.2. Results in the Subgroup of New HIV Diagnoses (n =
2928). In this subgroup of new HIV diagnoses (n = 2,928),
the median time to HIV diagnosis was 3.3 years (IQR: 1.6–
5.7) (Table 3), longer than the median of 2.8 years estimated
for the whole cohort.
These diﬀerences can partly be explained by the fact that
the739subjectsexcludedfromtheanalysesweresigniﬁcantly
diﬀerent (P<0.05) fromthe2,928 whowereincluded; in the
following ways, they were younger at diagnosis (mean age 30
versus 36 years) and at seroconversion (mean age 28 versus
32 years); they were more frequently IDUs (38.2% versus
10.1%); they were more often of Spanish origin (75.0%
versus 66.9%).
Table 2 shows the distribution of late diagnosis and the
results of the multivariate analysis in this subcohort. Unlike
what was seen in the whole cohort of 3,667 subjects, IDUs
had a higher frequency of late diagnoses compared with
MSM. Subjects with heterosexual transmission also had a
signiﬁcantly higher frequency of late diagnoses than MSM.
With regard to sex, age of diagnosis, and country of
origin, the results were similar to those for the whole cohort.
Table 3 shows the estimated time to HIV diagnosis in this
group and the percentage of delayed diagnoses according to
the deﬁnition DD. For each of the sociodemographic charac-
teristicsstudiedinthesubgroupof2,928newHIVdiagnoses,
we observed high consistency, except in women, between
time from imputed seroconversion date to HIV diagnosis
and frequency of delayed diagnoses (DD).
4. Discussion
This study illustrates the application of a multiple impu-
tation method to estimate the date of HIV seroconversion
in a cohort of seroprevalent patients who are not all newly
diagnosedwithHIVatentry.Wedeﬁnedaslatediagnosisthe
subjects with times to HIV diagnosis longer than 4.19 years.
The advantage of this deﬁnition is that it allows estimation
of late diagnosis in the whole cohort and not just in patients
with CD4 markers close to the time of HIV diagnosis.
Half of the cohort members were not diagnosed with
HIV until 2.8 years after becoming infected, and one fourth
were not diagnosed until 5.2 years after infection. Based on
the multivariate analysis, the time between the imputed date
ofHIVseroconversionandHIVdiagnosiswaslongerinmen,
increased with age, and was longer in persons from Sub-Sa-
haran Africa and Latin America compared to Spaniards. In
contrast, half of the new HIV diagnoses at entry into the
cohort were not diagnosed until 3.3 years after their imputed4 AIDS Research and Treatment
Table 1: Years between imputed date of seroconversion and date of HIV diagnosis in the whole cohort (n = 3667).
Years between imputed date of seroconversion and date of HIV diagnosis
N Median (P25–P75) Mean P
Sex <0.001
Men 2854 2.90 (1.24–5.40) 3.66
Women 813 2.32 (0.98–4.60) 3.15
Age at HIV diagnosis <0.001
Up to 20 158 1.31 (0.49–2.55) 1.66
21–30 1239 2.11 (0.86–4.36) 2.93
31–40 1361 2.99 (1.32–5.56) 3.78
41–50 599 3.67 (1.70–6.05) 4.25
51–60 219 4.16 (2.18–6.44) 4.59
Over 60 74 4.27 (2.22–6.42) 4.57
Not available 17 3.66 (2.04–5.57) 4.11 —
Transmission category <0.001
Injection drug user 578 1.82 (0.59–4.40) 2.87
Men who have sex with men 1581 2.73 (1.25–5.17) 3.57
Heterosexual risk exposure 1376 3.08 (1.38–5.53) 3.76
Other (vertical, transfusions, tattoos, etc.) 58 3.03 (1.33–5.48) 3.63
Don’t know/No answer 74 3.81 (1.83–6.10) 4.28
Educational level 0.790
No education or less than primary 257 2.88 (1.07–5.20) 3.46
Primary 1214 2.68 (1.09–5.20) 3.49
Secondary completed 1011 2.79 (1.22–5.25) 3.57
University completed 524 2.84 (1.29–5.33) 3.66
Not available 661 2.75 (1.19–5.20) 3.54 —
Country of origin 0.011
Spain 2512 2.57 (1.07–5.06) 3.42
Western Europe 114 2.96 (1.23–5.40) 3.74
Eastern Europe and Russia 72 2.97 (1.46–5.16) 3.58
Sub-Saharan Africa 246 3.54 (1.68–5.88) 4.04
North Africa 58 3.89 (1.77–6.35) 4.51
Latin America 631 3.04 (1.36–5.45) 3.71
Other/not available 34 2.84 (1.46–5.25) 3.77
AIDS <0.001
Yes 633 4.13 (2.01–6.19) 4.32
No 3034 2.49 (1.09–4.90) 3.38
Death 0.081
Yes 86 4.08 (1.84–6.12) 4.25
No 3581 2.73 (1.16–5.21) 3.53
Total 3667 2.76 (1.17–5.24) 3.54
HIV seroconversion date, and diagnostic delay was more
common in IDUs.
By imputing the date of seroconversion, we have shown
that the magnitude of late diagnosis in the whole cohort
was smaller than in the subgroup of new diagnoses (34%
versus 39%). In addition, we found diﬀerences not only in
the magnitude of late diagnosis but also in the associated risk
factors. These diﬀerences reﬂect the important changes in
HIV epidemiology, and probably in HIV testing practices as
well,thathavetakenplaceinSpaininthelastdecade:amajor
reduction in the number of IDUs who were exposed to fre-
quentHIVtestingopportunities,togetherwithanincreasein
sexually acquired infections which continues to require more
active HIV testing approaches. As CoRIS is not population
based, these conclusions cannot be extrapolated to the whole
HIV-positive population in Spain.
Our group had already evaluated late diagnosis in the
cohort, but limited to those patients with an HIV diagnosis
close to the time of their inclusion in the cohort [16]. We had
observed a very high prevalence of late diagnoses in IDUs,AIDS Research and Treatment 5
Table 2: Factors associated with late diagnosis (time to HIV diagnosis over 4.19 years).
Whole cohort (N = 3667) New HIV diagnoses (N = 2928)
LD∗/Total % Adjusted OR
(95% CI) P LD∗/Total % Adjusted OR
(95% CI) P
Sex
Men 1018/2854 36 1.67 (1.27–2.21) <0.001 936/2287 41 1.77 (1.30–2.40) <0.001
Women 233/813 29 1 211/641 33 1
Age at HIV diagnosis <0.001 <0.001
Up to 30 337/1397 24 1 296/964 31 1
31–40 498/1361 37 1.79 (1.46–2.19) <0.001 459/1133 41 1.49 (1.19–1.87) <0.001
Over 41 408/892 46 2.64 (2.10–3.30) <0.001 392/830 47 1.95 (1.56–2.45) <0.001
Not available 7/17 42 1.99 (0.61–6.54) 0.256 1/1 — — 0.808
Transmission category 0.055 0.043
Injection drug user 154/578 27 0.83 (0.62–1.09) 0.176 136/296 46 1.60 (1.10–2.32) 0.014
Men who have sex with
men 526/1581 33 1 479/1339 36 1
Heterosexual risk exposure 516/1376 37 1.26 (0.98–1.62) 0.069 483/1187 41 1.39 (1.06–1.82) 0.016
Other (vertical,
transfusions, tattoos, etc.) 21/58 37 1.08 (0.56–2.09) 0.820 20/46 44 1.36 (0.68–2.72) 0.385
Don’t know/No answer 34/74 45 1.47 (0.77–2.79) 0.241 30/60 50 1.70 (0.89–3.21) 0.105
Country of origin 0.004 0.065
Spain 812/2512 32 1 743/1958 38 1
Western Europe 41/114 36 1.14 (0.68–1.93) 0.615 34/82 41 1.11 (0.59–2.09) 0.744
Eastern Europe and Russia 25/72 35 1.48 (0.77–2.86) 0.243 23/64 37 1.13 (0.56–2.29) 0.731
Sub-Saharan Africa 104/246 42 1.75 (1.20–2.56) 0.004 95/215 44 1.54 (1.04–2.29) 0.032
North Africa 27/58 47 1.75 (0.85–3.59) 0.129 27/56 49 1.49 (0.70–3.14) 0.297
Latin America 231/631 37 1.38 (1.09–1.74) 0.008 214/522 41 1.38 (1.08–1.75) 0.009
Other/not available 11/34 34 0.96 (0.39–2.34) 0.925 11/31 36 0.92 (0.39–2.18) 0.846
Total 1251/3667 34 1147/2928 39
∗LD.: Late diagnosis (patients with time to HIV diagnosis over 4.19 years).
a result that diﬀered from other studies carried out in Spain
which described very high HIV testing uptake in IDUs [12,
17, 18]. Here, by imputing the date of seroconversion, which
allows study of the whole cohort, we no longer see a higher
frequency of late diagnoses in IDUs although this pattern
continues to be seen in the subgroup of new diagnoses. What
this reﬂects is that IDUs diagnosed with HIV before cohort
entry—in drug attention centers—were excluded from the
analyses. Together with a marked decline in the number of
IDUs among new HIV diagnoses in Spain, the analyses of
late HIV diagnosis within the surveillance system have also
identiﬁed a higher frequency of late diagnosis among IDUs
[23]. Consistent with previous publications from Spain and
other countries [12, 13, 16, 17, 23], late diagnosis is higher in
men, in migrants from non-Western countries, and increases
with age.
The results of this study are also important for compar-
ison purposes as the proportion of new HIV diagnoses in a
cohortmayvarybetweencohortsandwithinthesamecohort
over time. For example, cohorts may increase the number
of recruiting sites, or HIV incidence may change in a given
group. In this work, we highlight the fact that new HIV
diagnoses do not represent the whole cohort and that their
relative contribution needs to be taken into account when
comparingdiﬀerentcohortsorwheninterpretingtrendsover
time.
Our results are based on imputing the date of serocon-
version by using the ﬁrst available CD4 percentage from each
patient while oﬀ treatment. Other authors have observed
that this estimate can be improved by using the evolution of
various CD4 measurements [24, 25]. We also performed this
imputationprocessforeachmeasurementofCD4percentage
and estimated the date of seroconversion as the median date
of seroconversion estimated by the imputation for each value
of CD4. No diﬀerences were found with this analysis; the
median date of seroconversion was 1 July 2002. This may
be because the median number of CD4 measurements in
persons oﬀ treatment was only two, since most people start
treatment soon after entry.
We also conducted several sensitivity analyses using dif-
ferent assumptions about the date of initial risk, and the re-
sults were similar.
To evaluate the inﬂuence of the distribution model ini-
tially selected to impute the date of seroconversion [10], we
analyzed the data based on Weibull models with diﬀerent
parameters which, in some cases, permitted a subject to have6 AIDS Research and Treatment
Table 3: Years between the imputed date of seroconversion and the date of HIV diagnosis. Results in the subcohort of new diagnoses
(n = 2928).
Years between imputed date of seroconversion and date of HIV diagnosis
N %D D ∗ Median (P25–P75) Mean P
Sex <0.001
Men 2287 51.8 3.42 (1.65–5.83) 4.07
Women 641 50.2 2.77 (1.32–5.04) 3.51
Age at HIV diagnosis <0.001
Up to 20 93 33.3 1.94 (1.08–3.05) 2.15
21–30 871 39.6 2.76 (1.33–5.01) 3.46
31–40 1133 52.0 3.36 (1.62–5.89) 4.09
41–50 549 61.9 3.83 (1.87–6.18) 4.38
51–60 209 69.9 4.22 (2.25–6.42) 4.60
Over 60 72 75.0 4.37 (2.29–6.47) 4.63
Not available 1 100.0 5.25 (5.25–5.25) 5.25 —
Transmission category 0.111
Injection drug user 296 66.6 3.86 (1.93–6.11) 4.34
Men who have sex with men 1339 41.3 2.97 (1.42–5.43) 3.77
Heterosexual risk exposure 1187 58.0 3.39 (1.62–5.79) 4.00
Other (vertical, transfusions, tattoos, etc.) 46 63.0 3.71 (2.02–5.94) 4.18
Don’t know/No answer 60 63.3 4.18 (2.12–6.44) 4.57
Educational level 0.640
No education or less than primary 187 63.1 3.62 (1.77–5.85) 4.06
Primary 928 57.0 3.40 (1.62–5.82) 4.05
Secondary completed 853 46.0 3.13 (1.48–5.57) 3.85
University completed 443 41.3 3.07 (1.48–5.55) 3.85
Not available 517 54.9 3.30 (1.61–5.61) 3.96 —
Country of origin 0.410
Spain 1958 49.4 3.14 (1.49–5.58) 3.87
Western Europe 82 50.0 3.47 (1.77–5.80) 4.19
Eastern Europe and Russia 64 51.6 3.15 (1.59–5.33) 3.74
Sub-Saharan Africa 215 61.9 3.73 (1.82–6.05) 4.21
North Africa 56 60.7 4.09 (1.88–6.49) 4.62
Latin America 522 54.8 3.43 (1.70–5.81) 4.04
Other/not available 31 38.7 3.09 (1.52–5.73) 3.97
All 2928 51.4 3.26 (1.56–5.68) 3.94
∗DD: Delayed diagnosis (patients with CD4 count <350cells/mm3 in the ﬁrst year after HIV diagnosis or with AIDS-deﬁning disease in the the ﬁrst three
months after HIV diagnosis).
been infected for 30 years at the time of CD4 measurement.
The results obtained did not diﬀer substantially from those
presented.
Time to HIV diagnosis and delayed diagnosis (DD)
was not highly consistent in women. Some studies have
shown that, after seroconversion, women take longer than
men to reach the same CD4 level [20, 26]. Lodi et al.
estimate these diﬀerences at between 6 and 12 months
[20]. We conducted an analysis considering for women a
Weibull distribution with the same shape parameter, but
with a median of 9 months longer than for men. In this
simulation, diﬀerences between men and women in time
to diagnosis and in the percentage of late diagnosis dis-
appear.
In conclusion, estimates of the magnitude and risk fac-
tors of late HIV diagnoses for an entire cohort may diﬀer
from those obtained for new HIV diagnoses, a ﬁnding that
highlights the need to both improve and expand HIV testing
practices in our setting.
Appendix
Centersand InvestigatorsParticipating
inCoRIS
1. Coordinating Committee. Juan Berenguer, Julia del Amo,
Federico Garc´ ıa, F´ elix Guti´ errez, Pablo Labarga, Santiago
Moreno y Mar´ ıa ´ Angeles Mu˜ noz.AIDS Research and Treatment 7
2. Field Work, Data Management and Analysis. Ana Mar´ ıa
Caro-Murillo,PazSobrinoVegas,SantiagoP´ erez-Cachafeiro,
Victoria Hernando Sebasti´ an, Bel´ en Alejos Ferreras, D´ ebora
´ Alvarez, Susana Monge, Inma Jarr´ ın, M´ onica Trastoy.
3. BioBanco. M ´ Angeles Mu˜ noz-Fern´ andez, Isabel Garc´ ıa-
Merino, Coral G´ o m e zR i c o ,J o r g eG a l l e g od el aF u e n t ey
Almudena Garc´ ıa Torre.
4. Participating Centers
Hospital General Universitario de Alicante (Alicante). Joaq-
u´ ın Portilla Sogorb, Esperanza Merino de Lucas, Sergio Reus
Ba˜ nuls, Vicente Boix Mart´ ınez, Livia Giner Oncina, Carmen
Gadea Pastor, Irene Portilla Tamarit, Patricia Arcaina Toledo.
Hospital Universitario de Canarias (Santa Cruz de Tenerife).
Juan Luis G´ omez Sirvent, Patricia Rodr´ ıguez Fort´ unez,
Mar´ ıa Remedios Alem´ an Valls, Mar´ ıa del Mar Alonso Socas,
Ana Mar´ ıa L´ opez Lirola, Mar´ ıa Inmaculada Hern´ andez
Hern´ andez, Felicitas D´ ıaz-Flores.
Hospital Carlos III (Madrid). Vicente Soriano, Pablo Labar-
ga, Pablo Barreiro, Carol Casta˜ nares, Pablo Rivas, Andr´ es
Ruiz, Francisco Blanco, Pilar Garc´ ı a ,M e r c e d e sd eD i e g o .
Hospital Universitario Central de Asturias (Oviedo). Victor
Asensi, Eulalia Valle, Jos´ e Antonio Cart´ on.
Hospital Clinic (Barcelona). Jos´ eM .M i r ´ o, Mar´ ıa L´ opez-
Dieguez, Christian Manzardo, Laura Zamora, I˜ naki P´ erez,
Ma Teresa Garc´ ıa, Carmen Ligero, Jos´ eL u i sB l a n c o ,F e l i p e
Garc´ ıa-Alcaide, Esteban Mart´ ınez, Josep Mallolas, Jos´ eM .
Gatell.
Hospital Doce de Octubre (Madrid). Rafael Rubio, Federico
Pulido, Silvana Fiorante, Jara Llenas, Violeta Rodr´ ıguez,
Mariano Matarranz.
Hospital Donostia (San Sebasti´ an). Jos´ e Antonio Iribarren,
Julio Arrizabalaga, Mar´ ıa Jos´ e Aramburu, Xabier Camino,
Francisco Rodr´ ıguez-Arrondo, Miguel ´ Angel von Wich-
mann, Lidia Pascual Tom´ e, Miguel ´ Angel Goenaga, Ma Jes´ us
Bustinduy, Harkaitz Azkune Galparsoro.
Hospital General Universitario de Elche (Elche). F´ elix Gut-
i´ errez, Mar Masi´ a, Jos´ e Manuel Ramos, Sergio Padilla,
Andr´ esNavarro,FernandoMontolio,YolandaPeral,Catalina
Robledano Garc´ ıa.
Hospital Germans Tr´ ıas i Pujol (Badalona). Bonaventura
Clotet, Cristina Tural, Lidia Ruiz, Cristina Miranda, Roberto
Muga, Jordi Tor, Arantza Sanvisens.
H o s p i t a lG r e g o r i oM a r a ˜ n´ on (Madrid). Juan Berenguer, Juan
CarlosL´ opezBernaldodeQuir´ os,PilarMiralles,JaimeCos´ ın
Ocha´ ıta, Matilde S´ anchez Conde, Isabel Guti´ errez Cuellar,
Margarita Ram´ ırez Schacke, Bel´ en Padilla Ortega, Paloma
Gij´ on Vidaurreta.
Hospital Universitari de Tarragona Joan XXIII, IISPV, Uni-
versitat Rovira i Virgili (Tarragona). Francesc Vidal, Joaqu´ ın
Peraire, Consuelo Vilad´ es, Sergio Veloso, Montserrat Vargas,
Miguel L´ opez-Dupla, Montserrat Olona, Joan-Josep Sirvent,
Alba Aguilar, Antoni Soriano.
Hospital Universitario La Fe (Valencia). Jos´ eL´ opez Aldeguer,
Marino Blanes Juli´ a, Jos´ eL a c r u zR o d r i g o ,M i g u e lS a l a v e r t ,
M a r t aM o n t e r o ,E v aC a l a b u i g ,S a n d r aC u´ ellar.
Hospital Universit´ ario La Paz (Madrid). Juan Gonz´ alez
Garc´ ıa, Ignacio Bernardino de la Serna, Jos´ eM a r ´ ıa Pe˜ na
S´ anchez de Rivera, Marta Mora Rillo, Jos´ eR a m ´ on Arribas
L´ opez, Mar´ ıa Luisa Montes Ram´ ırez, Jos´ e Francisco Pascual
Pareja, Blanca Arribas, Juan Miguel Castro, Fco Javier Zam-
ora Vargas, Ignacio P´ erez Valero.
Hospital de la Princesa (Madrid). Ignacio de los Santos, Jes´ us
Sanz Sanz, Johana Rodr´ ıguez, Ana Salas Aparicio, Cristina
Sarri´ aC e p e d a .
Hospital San Pedro-CIBIR (Logro˜ no). Jos´ e Antonio Oteo,
Jos´ eR a m´ on Blanco, Valvanera Ibarra, Luis Metola, Mercedes
Sanz, Laura P´ erez-Mart´ ınez.
Hospital San Pedro II (Logro˜ no). Javier Pinilla Moraza.
Hospital Universitario Mutua de Terrassa (Terrassa). David
Dalmau, Angels Ja´ en Manzanera, Mireia Cair´ o Llobell, Dan-
iel Irigoyen Puig, Laura Ib´ a˜ nez, Queralt Jordano Monta˜ nez,
Mariona Xercavins Valls, Javier Martinez-Lacasa, Pablo Velli,
Roser Font.
Hospital de Navarra (Pamplona). Julio Sola Boneta, Javier
Uriz, Jes´ us Castiello, Jes´ us Reparaz, Mar´ ıa Jes´ us Arraiza, Car-
men Irigoyen, David Mozas.
Hospital Parc Taul´ ı (Sabadell). Ferr´ an Segura, Mar´ ıa Jos´ e
Amengual, Eva Penelo, Gemma Navarro, Montserrat Sala,
Manuel Cervantes, Valent´ ın Pineda.
Hospital Ram´ on y Cajal (Madrid). Santiago Moreno, Jos´ e
Luis Casado, Fernando Dronda, Ana Moreno, Mar´ ıa Jes´ us
P´ erez El´ ıas, Dolores L´ opez, Carolina Guti´ errez, Beatriz
Hern´ andez, Mar´ ıa Pumares, Paloma Mart´ ı.
Hospital Reina Sof´ ıa (Murcia). A l f r e d oC a n oS ´ anchez, En-
rique Bernal Morell, ´ Angeles Mu˜ noz P´ erez.
Hospital San Cecilio (Granada). Federico Garc´ ıa Garc´ ıa, Jos´ e
Hern´ andez Quero, Alejandro Pe˜ na Monje, Leopoldo Mu˜ noz
Medina, Jorge Parra Ruiz.8 AIDS Research and Treatment
Centro Sanitario Sandoval (Madrid). Jorge Del Romero
Guerrero, Carmen Rodr´ ıguez Mart´ ın, Teresa Puerta L´ opez,
Juan Carlos Carri´ o Montiel, Cristina Gonz´ alez.
Hospital Universitario Santiago de Compostela (Santiago de
Compostela). Antonio Antela, Arturo Prieto, Elena Losada.
Hospital Son Dureta (Palma de Mallorca). Melchor Riera,
Javier Murillas, Maria Pe˜ naranda, Maria Leyes, Ma Angels
Ribas, Antoni Campins, Concepcion Villalonga.
Hospital Universitario de Valme (Sevilla). Juan Antonio Pin-
eda, Eva Recio S´ anchez, Fernando Lozano de Le´ on, Juan
Mac´ ıas, Jos´ ed e lV a l l e ,J e s´ us G´ omez-Mateos, Rosario Mata.
Hospital Virgen de la Victoria (M´ alaga). Jes´ us Santos
Gonz´ alez, Manuel M´ arquez Solero, Isabel Viciana Ramos,
Rosario Palacios Mu˜ noz.
Hospital Universitario Virgen del Roc´ ıo (Sevilla). Pompeyo
Viciana, Manuel Leal, Luis Fernando L´ opez-Cort´ es, M´ onica
Trastoy.
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